Eidos Therapeutics Inc.
- Address
- 1800 Owens Street Suite C1200
Sponsor Overview
Specializations
Transthyretin Amyloid Cardiomyopathy
Eidos Therapeutics Inc. focuses on clinical research in symptomatic transthyretin amyloid cardiomyopathy, with attention to disease control, cardiac function, and the safety and tolerability of acoramidis in people living with established ATTR-CM.
- Symptomatic ATTR-CM
- Cardiac amyloidosis
- Cardiovascular disease management
The sponsor also supports longer-term clinical follow-up in newly diagnosed patients, reflecting continued interest in the management of progressive amyloid-related heart disease.
Transthyretin Amyloidosis Prevention
Another major area of interest is prevention of transthyretin amyloidosis in asymptomatic carriers of pathogenic TTR variants, with research directed toward delaying or preventing the onset of clinical disease in individuals at inherited risk.
- Asymptomatic TTR variant carriers
- Hereditary amyloidosis
- Early intervention in ATTR risk
This includes attention to both ATTR-CM and ATTR-PN as clinically relevant outcomes in people who have not yet developed overt disease.
Long-Term Safety and Tolerability
The sponsor’s research portfolio includes extended observation of acoramidis in transthyretin amyloidosis, with emphasis on sustained safety, tolerability, and ongoing treatment experience across affected populations.
- Long-term safety
- Tolerability monitoring
- Extended treatment follow-up
These studies address both people with established ATTR-CM and those being monitored for future development of amyloid disease.
Inherited Amyloid Disease
Eidos Therapeutics Inc. is active in research on inherited forms of amyloidosis, particularly conditions linked to pathogenic TTR variants and their impact on the heart and peripheral nerves.
- Genetic TTR disorders
- Familial amyloidosis
- ATTR-related organ involvement
The clinical focus spans both diagnosed disease and presymptomatic risk, covering the spectrum of transthyretin-mediated illness.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE) |  Belgium Denmark France Germany Greece Ireland Italy Portugal Spain Sweden The Netherlands | Not Yet Recruiting |
| Open-Label Extension and Safety Evaluation of Acoramidis Hydrochloride in Symptomatic Transthyretin Amyloid Cardiomyopathy Post-Phase 3 ATTRibute-CM Completion | Belgium Czechia Denmark Greece Ireland Italy Portugal Spain The Netherlands | Not Recruiting |
| Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acoramidis Hydrochloride for Transthyretin Amyloidosis Prevention in Asymptomatic TTR Variant Carriers | Belgium Bulgaria Denmark France Germany Greece Ireland Italy Portugal Spain Sweden The Netherlands | Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 45 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases3 trials359 other sponsors
- 2.Nervous System Diseases2 trials449 other sponsors
Partnered Research Centres
45 centres- Address
- Via Consolare Valeria N 1, 98124 Messina
- Address
- Palle Juul-Jensens Boulevard 99, 8200 Aarhus
- Address
- Vassilissis Sofias Avenue 80, 115 28 Athens
- Address
- Ruddershove 10, 8000 Bruges
- Address
- Largo Giovanni Alessandro Brambilla 3, 50134 Florence
- Address
- Via Di Grottarossa 1035-1039, 00189 Rome
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Eidos Therapeutics Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.